AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$REGN

Pitofsky Jason sold $3.7M of REGN

Pitofsky Jason (SVP Controller) sold 3,883 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at an average of $941.79 ($939.57–$945.61, $3.66M total) across 7 trades on 2026-11-04.

Original reporting
SEC EDGAR · Pitofsky Jason
Published Nov 6, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$REGN
Bearish
medium confidence
Mentioned
$REGN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REGNBearishLow
01

Why it matters

The transaction reduces insider ownership and may be interpreted as a negative signal, but the size is modest relative to market cap.

02

Market read

A routine insider sale with limited market impact; traders may watch for any follow‑up activity.

03

What to watch

No 10b5‑1 plan; sale may be unrelated to company fundamentals.

Relevance 6/10Novelty 4/10Timing: post‑market today

Background

Regeneron Pharmaceuticals (REGN) disclosed a Form 4 filing where senior controller Jason Pitofsky sold nearly 4,000 shares.

Company-level read

Ticker impact

$REGNBearishMedium confidence
Context

Form 4 shows insider Jason Pitofsky sold 3,883 shares for $3.66M, reducing his stake to 4,272 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A senior officer sold multi‑million dollars of stock; while the amount is not huge, such sales often prompt short‑term selling.

Market effects

Sector

Minimal impact on biotech sector; isolated insider transaction.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • company
    Regeneron Pharmaceuticals, Inc.

    Biotech firm listed on NASDAQ.

  • person
    Jason Pitofsky

    Senior Vice President, Controller at Regeneron.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

REGN insider trading history →

Related articles

$LLYHighAI 8/10

Eli Lilly, Regeneron Lead Weight-Loss ETF THNR Higher

Eli Lilly (LLY) and Regeneron (REGN) led gains in the VettaFi Weight Loss Drug & Treatment Index, which rose 3.28% in October. Lilly's Q3 revenue of $24.4B beat estimates, and it raised its 2026 forecast. Regeneron's revenue jumped 36%. AstraZeneca (AZN) and Roche also contributed to the index's gains, while CSPC Pharmaceutical Group and Structure Therapeutics fell.

etfdb.com
HighAI 8/10

Why is Regeneron Pharmaceuticals stock surging today?

Regeneron Pharmaceuticals' stock rose 4.0% to a 52-week high of $972.06 after reporting Q3 2026 earnings of $20.07 per share, up 70% Y/Y, and revenue of $5.116B, up 36% Y/Y. Multiple analysts raised price targets, with BofA Securities at $1,030 and Canaccord Genuity at $1,175. Positive Phase 3 trial data for Libtayo also supported the stock.

investing.com
$REGNMedAI 9/10

Regeneron Stock Jumps 13% to 52-Week High as Sanofi Dupixent Windfall Powers a Blockbuster Third Quarter

Regeneron (REGN) shares rose 13.33% to a 52-week high after reporting Q3 earnings and revenue above expectations, driven by its partnership with Sanofi on Dupixent. Adjusted earnings were $20.07 per share, up 70% YoY, and revenue rose 36% to $5.12 billion. Collaboration revenue from Sanofi reached $2.7 billion, up 68% YoY. The company also expanded its alliance with Sanofi, with a $1 billion upfront payment expected in Q4.

ibtimes.com.au